hVIVO (LON:HVO) Stock Price Passes Below Fifty Day Moving Average - Time to Sell?

Key Points

• hVIVO plc's stock price fell below its 50-day moving average for the first time, currently trading at GBX 9.12 ($0.12), indicating a potential sell signal.
• Analysts have set new price targets for hVIVO, with Shore Capital maintaining a "buy" rating" and a target of GBX 35, while the consensus target price stands at GBX 28.
• The company's market cap is £67.33 million, with a price-to-earnings ratio of 632.06, reflecting high valuation expectations amidst its involvement in human challenge clinical trials.

Shares of hVIVO plc (LON:HVO - Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 10.15 ($0.14) and traded as low as GBX 9.12 ($0.12). hVIVO shares last traded at GBX 9.12 ($0.12), with a volume of 837,810 shares.

Analysts Set New Price Targets

Several research firms have recently issued reports on HVO. Shore Capital restated a "buy" rating and set a GBX 35 price objective on shares of hVIVO in a report on Tuesday, July 22nd. Peel Hunt restated an "add" rating and set a GBX 21 price objective on shares of hVIVO in a report on Tuesday, July 29th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of GBX 28.

hVIVO Stock Up 7.4%

The stock has a market cap of £67.33 million, a price-to-earnings ratio of 632.06 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a fifty day moving average of GBX 10.15 and a two-hundred day moving average of GBX 13.26.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.